Transdermal patch for treatment of schizophrenia hits Phase III goals

1 February 2018
research_technology_lab_big

Japanese drugmaker Hisamitsu Pharmaceuticals (TYO: 4530), along with US subsidiary Noven Pharmaceuticals, say their transdermal patch for the treatment of schizophrenia (HP-3070, generic name: asenapine maleate) has achieved the primary endpoint of the Phase III clinical trial in the USA.

This study was a Phase III clinical trial to evaluate the efficacy and safety of the investigational product in 617 patients diagnosed with schizophrenia. The primary endpoint of the study was change from baseline of the Positive and Negative Syndrome Scale (PANSS) total score. Efficacy and safety was assessed during the six-week application period.

The study results showed that when compared to placebo the investigational product achieved statistically-significant improvement from baseline in the change of the total PANSS score at six weeks. Secondary endpoints are still under review.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical